Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1, receptor agonist, has shown promise in promoting weight loss and improving ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide – a drug known as Zepbound™ – on weight ...

Even more encouragingly, most people maintained the weight loss for the entire three-year study. “Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be ...